Phillip Kuo, MD, PhD, Departments of Medical Imaging, Medicine, and Biomedical Engineering, University of Arizona, discusses the abstract, “[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy,” which was presented at the 2022 ASCO Annual Meeting.
The post-hoc exploratory analysis specifically showed that a higher whole-body SUVmean was strongly associated with improved long-term clinical outcomes among men in the VISION trial with PSMA-positive mCRPC on 68Ga-PSMA-11 PET/CT treated with 177Lu-PSMA-617.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.